AGN 190584

Drug Profile

AGN 190584

Alternative Names: AGN 190584

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allergan
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Presbyopia

Most Recent Events

  • 31 Oct 2017 Allergan completes a phase II trial for Presbyopia (Combination therapy) in USA (Opthalmic) (NCT02780115)
  • 18 Oct 2017 Allergan completes a phase II trial in Presbyopia (Combination therapy) in USA (Ophthalmic) (NCT02595528)
  • 01 May 2016 Allergan initiates a phase II trial for Presbyopia (Combination therapy) in USA (NCT02780115)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top